慢性乙肝基因分型与恩替卡韦抗病毒的临床研究

Genotyping and Entecavir Chronic Hepatitis b Antiviral Clinical Research

目的探讨慢性乙肝基因分型与恩替卡韦抗病毒的临床疗效。方法随机选取2014年5月—2016年6月于该院接受治疗的50例慢性乙肝患者为研究对象。全部患者均口服恩替卡韦进行抗病毒治疗,治疗前乙肝HBV基因分型检测,探究恩替卡韦对不同基因分型乙肝病毒的抗病毒效果。结果 C基因型乙肝患者74.0%(37/50),经恩替卡韦抗病毒治疗后,C基因型乙肝患者HBV-DNA低于检测下线率30例(81.08%),ALT复常率34例(91.89%),HBe Ag转阴率12例(38.71%),HBe Ag血清学转换率6例(16.22%),各项指标均优于其他基因型乙肝患者(P<0.05)。结论基因C型是盐城地区乙肝病毒最主要基因型,以恩替卡韦对该分型患者进行抗病毒治疗,其效果优于其他基因分型患者,值得临床使用推广。

Objective To investigate the clinical efficacy of chronic hepatitis B virus genotypes and the antiviral effect of.Methods Random selection 50 cases of chronic hepatitis B patients treated in our hospital from May 2014 to June 2016 were studied. All patients were treated with oral ex-Cave for antiviral therapy, HBV genotyping test before treatment, and to explore the effect of Cave on the antiviral effect of different genotypes of hepatitis B virus. Results The grace of entecavir antiviral therapy, genotype C HBV patients with HBV-DNA below the detection line rate of 30(81.08%), ALT normalization rate of 34(91.89%), HBe Ag negative conversion rate of 12(38.71%), HBe Ag seroconversion rate in 6(16.22%), the indicators were better than other genotypes of hepatitis B patients(P < 0.05).Conclusion The genotype C is Yancheng region of hepatitis B virus is the main genotype, such as entecavir in patients with the type of antiviral therapy and its effect is better than that of other genes into patients. It is worthy of clinical use.